Published in Drug Law Weekly, January 16th, 2007
The company intends to use the proceeds from the financing to prepare for the potential commercial launch of Amoxicillin Pulsys, to continue product development initiatives of its other pulsatile product candidates, and for working capital and general corporate purposes.
The shares sold in the private placement have not been registered under the Securities...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Drug Law Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.